Back to the atlasDownload source notes

September 27, 2026 — scheduled research update

Home · Latest · Calendar

Research checked through September 27, 2026. Searched from the last successful topic checks with a seven-day overlap (September 5–6 onward), prioritizing September 23–27. Original source/event dates and baseline labels are preserved.

34 deduplicated sourced entries, 7 unchanged informal-claim follow-ups, and 28 focused topic checks. All topic checks remain partial; full successful-check timestamps are preserved. A search gap is not a no-news conclusion.

Findings

  • Verified 2026-09-27; posting date unknown — BELIEVE abstract describes six months after treatment withdrawal. Official conference abstract available before scheduled presentation. Notes.
  • 2026-09-25 — NOHARM reduces opioid exposure without improving pain interference or function. Peer-reviewed cluster randomized trial. Notes.
  • 2026-09-25 — OCU400 receives provisional Bahamas designation; treatment access still conditional. Sponsor report of foreign regulatory/access milestone. Notes.
  • 2026-09-24 — FDA approves belzutifan plus lenvatinib after immunotherapy for advanced kidney cancer. FDA approval and randomized phase 3 evidence. Notes.
  • 2026-09-24 — Setidegrasib begins phase 3 dosing in KRAS G12D lung cancer. Sponsor human-trial initiation. Notes.
  • 2026-09-24 — FDA approves once-weekly Onswik insulin for type 2 diabetes. FDA regulatory action. Notes.
  • 2026-09-24 — Fasedienol exploratory and open-label findings follow the failed PALISADE-4 primary endpoint. Sponsor preliminary open-label and subgroup analyses. Notes.
  • 2026-09-24 — Remlifanserin misses Alzheimer psychosis primary endpoint; phase 3 continues. Sponsor phase 2 randomized topline results. Notes.
  • 2026-09-24 — Remigromig meets vision noninferiority endpoint but shows more retinal adverse events. Sponsor phase 2b/3 randomized topline results. Notes.
  • 2026-09-24 — A placebo-controlled hair-graying trial enters the registry. trial-registry registration. Notes.
  • 2026-09-24 — Small lipedema trial finds no clear advantage for shockwave treatment. peer-reviewed randomized human study; primary abstract appraised. Notes.
  • 2026-09-23 — Galleri advisory panel votes favorably; FDA decision remains pending. FDA advisory-committee record. Notes.
  • 2026-09-23 — FDA approves lirafugratinib for previously treated FGFR2-altered bile-duct cancer. FDA approval with single-arm evidence. Notes.
  • 2026-09-23 — Anito-cel phase 1 publication pairs durable responses with substantial toxicity. Peer-reviewed uncontrolled phase 1 study. Notes.
  • 2026-09-23 — Sefaxersen meets interim IgA-nephropathy proteinuria endpoint. Sponsor Phase 3 interim topline. Notes.
  • 2026-09-23 — IMVT-1402 cutaneous-lupus study misses primary endpoint; indication discontinued. Sponsor topline randomized human trial. Notes.
  • 2026-09-23 — ORKA-001 psoriasis responses persist to week 28 after dosing ended at week 4. Sponsor phase 2a follow-up. Notes.
  • 2026-09-23 — Human tissue study investigates persistent CAR-T-associated enterocolitis. Peer-reviewed observational human study. Notes.
  • 2026-09-23 — XanaMIA completes final participant visit; November readout forecast retained. Sponsor operational milestone. Notes.
  • 2026-09-23 — Hair-follicle secretome presentation announced, with very early skin-recovery data. investigator/practice announcement; preliminary human study and conference schedule. Notes.
  • 2026-09-22 — Enicepatide reports Phase 2 diabetes and weight-loss results. Sponsor topline announcement. Notes.
  • 2026-09-22 — TST002 adds early bone-density data and a Phase 2 study to watch. Peer-reviewed Phase 1 abstract and trial registry. Notes.
  • 2026-09-21 — New-to-watch PCSK9 epigenetic-silencing program is recruiting. Baseline addition. Trial registry and sponsor/investigator baseline. Notes.
  • 2026-09-21 — Evolocumab trial will test AI-measured subclinical coronary plaque. Baseline addition. New-to-watch trial registration. Notes.
  • 2026-09-18 — FDA expands imlunestrant use to a combination for ESR1-mutated advanced breast cancer. FDA approval and randomized trial subgroup. Notes.
  • 2026-09-18 — Short pharmacogenomic hypertension trial reports better blood-pressure control, with major design limits. Peer-reviewed open-label randomized trial. Notes.
  • 2026-09-18 — Two-year pulp-preservation trial finds no superiority of a newer cement. peer-reviewed randomized human study; full text and registry appraised. Notes.
  • 2026-09-17 — OCTOPUS stops metformin arm in progressive MS for insufficient promise. Investigator interim adaptive-trial decision. Notes.
  • 2026-09-17 — BGM0504 Phase 2 obesity trial gains a peer-reviewed report. Peer-reviewed randomized trial; primary abstract reviewed. Notes.
  • 2026-09-16 — SOLARIO supports shorter systemic antibiotics when surgery includes local antibiotic implants. Peer-reviewed randomized noninferiority trial. Notes.
  • 2026-09-15 — Completed senolytic trial will test physical function in older adults with HIV. Baseline addition. New-to-watch completed-trial registry. Notes.
  • 2026-09-15 — Delgocitinib facial-vitiligo study newly registered after enrollment. trial-registry registration. Notes.
  • 2026-09-08 — Facial-fat-graft registry will measure one-year volume retention. trial-registry record; new-to-watch study. Notes.
  • 2026-09-04 — New-to-watch radiofrequency-versus-topical acne trial. Baseline addition. trial-registry record; recovered baseline. Notes.

Coverage and remaining gaps

Whole-body MRI

Status: focused, partial. Searched September 5–27 human whole-body screening evidence, HERCULES and review publications. New AJR expert review is not a new screening-outcome trial.

Gaps: Full AJR review, registry history and downstream outcome papers were not completely appraised; no comprehensive international registry census.

Informal sources: Reddit and screening-discussion searches mainly found personal experience and commercial claims. No new attributable trial-result rumor selected; full podcast audio not reviewed.

Sources checked: Source 1; Source 2; Source 3.

Galleri and organ-specific cancer screening

Status: focused, partial. Read FDA September 23 24-hour summary and sponsor vote announcement; deduplicated prior September 22 repeat-screening papers. Followed elapsed advisory milestone.

Gaps: Full meeting transcript/webcast not appraised; organ-specific colorectal and other screening registries require further refresh. FDA final decision remains pending in reviewed sources.

Informal sources: September 23–24 Reddit posts repeat verified votes or speculate about approval without a new evidenced date; no separate alert. https://www.reddit.com/r/Wiseek/comments/1wok3yj/gral_fda_panel_backs_grails_galleri_cancer_test/

Sources checked: Source 1; Source 2; Source 3.

Status: focused, partial. September 5–27 overlap, prioritizing September 23–27: Roche CT-388 diabetes, BGM0504 publication, insulin approval, EASD official schedule and new human-program discovery. Deduplicated VK2735/CagriSema announcements.

Gaps: CT-388 registry/release endpoint timing unresolved; placebo effects and estimand absent. BGM0504 full paper inaccessible. Not a complete worldwide incretin registry/safety census.

Informal sources: Searched Reddit enicepatide/retatrutide and conference forecasts. September 26 self-reported trial participant thread mainly anecdotes and an unverified upcoming-diabetes-presentation claim; no additional efficacy rumor promoted. Original: https://www.reddit.com/r/antidietglp1/comments/1wqerf2/week_one/ . Roche public EASD agenda checked; no assumption that every enicepatide talk is new diabetes readout.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7; Source 8; Source 9.

Muscle building and preservation

Status: focused, partial. BELIEVE EASD six-month withdrawal abstract/schedule; bimagrumab/tirzepatide original registry; Veru program and SRK/deramiocel searches.

Gaps: BELIEVE follow-up arm denominators and intervals absent; upcoming full slides not appraised. Bimagrumab/tirzepatide record remains old May26 snapshot with no results. Disease-specific and sarcopenia registry census incomplete.

Informal sources: Revisited existing Veru Cantor Phase 3 direction against company updates; no confirmed 4,500-person Phase 3 start. September 15 Reddit post repeats prior QUALITY/PLATEAU data; gray-market discussions excluded. https://www.reddit.com/r/suppgains/comments/1wh1doq/i_had_to_double_check_this_one/ . Original Cantor audio still not reviewed.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5.

Longevity and healthspan drug trials

Status: focused, partial. TAME direct status, metformin/rapamycin/senolytic discovery; IPACE-HIV primary registry, INSPIRE-COPD-E and MAVRIC original records.

Gaps: TAME funding/start remains unverified. INSPIRE-COPD-E remains not yet recruiting in stale April record despite elapsed September 1 estimate. MAVRIC remains not yet recruiting with September28 estimatedstart; disease-specific study not lifespan evidence. RESTOR not freshly downloaded; global census and full podcasts incomplete.

Informal sources: September 24 r/Aging senolytic-skin headline refers to mice and was excluded; September20 fisetin discussion not a new human-trial result. September25 Kara Fitzgerald show description and wider podcast searches did not disclose a verified new human-program milestone; original audio not reviewed. https://www.reddit.com/r/Aging/comments/1wosuw7/breakthrough_drug_reverses_skin_aging_and/ ; https://podcasts.apple.com/gb/podcast/what-actually-slows-aging-the-science-vs-hype-dr/id1103271110?i=1000791630630

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6.

Localized fat removal

Status: focused, partial. September 5–27 overlap with emphasis on September 23–27: CBL-514, RZL-012, AYP-101, tesamorelin, cellulite and human body-contouring/lipedema comparisons. Refreshed five original registry records and deduplicated CBL September 21/22 findings.

Gaps: SUPREME-01 remains recruiting, last posted September 22; September 30 visceral-fat presentation has not occurred. No independent new SUPREME-02 enrollment milestone established. AYP-101 remains completed without posted results. Tesamorelin record is unchanged; original liver-fat/VAT reporting limitations remain. Full cellulite-device comparative census and complete lipedema paper not appraised.

Informal sources: Targeted Reddit/talk searches for CBL-514, tesamorelin and cellulite mainly returned reposts of already recorded Dercum results, personal experiences and commercial claims; no new specific development rumor promoted.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7.

Broad cardiovascular prevention, lipid therapies and screening

Status: focused, partial. Lipid development and coronary plaque/CCTA discovery; verified STX-1150 and subclinical-evolocumab registries; pelacarsen September 25 JAMA news is a repeat of September 4 failure.

Gaps: No new verified VERVE Phase 2 start, full HORIZON statistics or final obicetrapib EC documents. Prevention/AI-CAC evidence census incomplete.

Informal sources: Reddit Lp(a) and plaque threads contain interpretations of already reported HORIZON/SCAPIS, not new outcome data. No new STX-1150 leak surfaced. Example: https://www.reddit.com/r/Cholesterol/comments/1w7h6r5/disapointing_outcome_for_pelacarsenlpa_horizon/ . Full podcast recordings not reviewed.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7; Source 8.

Alzheimer's screening and therapies

Status: focused, partial. Primary sponsor developments September 5–27; new XanaMIA milestone and RADIANT results; SPINOZA status; selected diagnostic and prevention searches.

Gaps: Not a complete registry/label refresh across all amyloid antibodies and screening programs. XanaMIA registry matching and detailed endpoints remain unverified; ALZ-101/PrevenTRON new-program leads not fully appraised. Full Acadia conference call, forthcoming CTAD packet and all safety tables unavailable or unreviewed.

Informal sources: Revisited Attia–Davidson episode/public notes and relevant Reddit discussion; no new confirmed cognitive-outcome evidence. Full paid transcript not reviewed.

Sources checked: Source 1; Source 2; Source 3.

Status: focused, partial. Selected sponsor and clinical-publication discovery since September 5; FDA hearing/MDMA resubmission follow-up; Definium and GH developments checked against prior events.

Gaps: September 14 FDA hearing full proceedings/transcripts not appraised; October 5 comment deadline remains future. Complete conference posters, current trial registries and underlying informal investor-call recordings not reviewed. No FDA acceptance/decision date independently verified for reported MDMA resubmission.

Informal sources: Reviewed psychedelic-stock discussion threads and reported MDMA refiling. A September EPISODE repost points to a March paper, not new results. Anonymous Compass filing/review-timing comments lacked an appraised original recording and added no sufficiently verified material update to the saved filing outlook.

Sources checked: Source 1; Source 2; Source 3.

Mental-health treatments, SSRIs and newer antidepressants

Status: focused, partial. Fasedienol September 22/24 OLE and subgroup releases, mental-health conference discovery and Alzheimer-psychosis cross-link; prior lumateperone event deduplicated.

Gaps: No full coverage of OCD, PTSD, bipolar disorder, addiction, liafensine or ansofaxine registries. Quantitative repeat-dose fasedienol poster not appraised; FDA meeting completion unknown. Digital-therapeutic and other September conference leads not fully appraised.

Informal sources: Targeted Reddit and sponsor-interview searches produced anecdotes/reposts without a new attributable material claim suitable for the rumor log; not comprehensive transcript coverage.

Sources checked: Source 1; Source 2; Source 3.

Cancer treatment, vaccines and recurrence prevention

Status: focused, partial. September 5–27 discovery with September 23–27 emphasis: FDA oncology actions, targeted-degrader phase 3 initiation, CAR-T publication and vaccine/cellular programs.

Gaps: Not a complete cancer/line-of-therapy census. Full ESMO/IMS/AACR abstracts, all safety appendices and confirmatory registries remain gaps. Some older negative trial leads await primary appraisal.

Informal sources: Searched sponsor interviews and Reddit/SELLAS discussion. REGAL outcome guesses and preclinical SLS009 pancreatic work do not establish human efficacy; no new original attributable milestone rumor selected. https://www.reddit.com/r/sellaslifesciences/comments/1worijt/sls_daily_discussion_thread_thursday_september_24/

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6.

Autoimmune disease modification and immune-reset therapies

Status: focused, partial. IMVT-1402 failure, ORKA-001 durability and human CAR-T gut-safety paper; selected RESET/rap-cel registries and restart searches.

Gaps: No complete ACR abstract or autoimmune program registry sweep. Rapcabtagene myositis registry active-not-recruiting status does not verify a clinical restart. Other IgG-lowering indications and full safety tables require separate checks.

Informal sources: IMVT Reddit discussion corroborated through the primary release. Revisited Mount Sinai IBD CAR-T planning interview; no trial-initiation confirmation. Investor speculation attributing safety to rapid manufacturing was not treated as causal evidence.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7; Source 8; Source 9; Source 10.

Sleep therapies and sleep disorders

Status: focused, partial. Orzeyful availability checked and three Brilliance orexin-agonist registry records refreshed; selected insomnia, apnea and hypersomnolence news searches.

Gaps: No complete insomnia, CBT-I/digital therapy, circadian or restless-legs study refresh. Orzeyful actual launch and DEA scheduling not verified; manufacturer still describes forthcoming availability. Full conference abstracts and safety-label changes not comprehensively reviewed.

Informal sources: September 27 narcolepsy discussion repeats a November expectation pending scheduling, not verified launch: https://www.reddit.com/r/Narcolepsy/comments/1wr7at2/new_medication_made_in_japan/. No separate alert for repeated forecast.

Sources checked: Source 1; Source 2; Source 3; Source 4.

Liver disease, fibrosis and noninvasive assessment

Status: focused, partial. MASH/liver human-trial discovery and saved Wegovy CHMP ambiguity follow-up; EMA current EPAR searched, Novo CMD/TGM/NATiV3 repeats deduplicated.

Gaps: Wegovy September CHMP outcome still unverified: current overview contains no MASH entry; absence is not a rejection. Full minutes/updated assessment not recovered. Pegozafermin, efimosfermin and noninvasive testing/clinical-outcome census incomplete.

Informal sources: Revisited September18 original Reddit CHMP omission claim; September23 post claims Singapore MASH approval but regulator corroboration not retrieved, so retained as discovery gap rather than approval fact. MASH podcast searches mainly CME, reviews and personal stories; no full audio review. Original: https://www.reddit.com/r/NovoNordisk_Stock/comments/1wjxoxg/wegovys_mash_indication_was_for_adoption_at_chmp/ ; https://www.reddit.com/r/NovoNordisk_Stock/comments/1wo0wv6/wegovy_expansion_mash_approval_in_singapore_72_mg/

Sources checked: Source 1; Source 2; Source 3.

Kidney preservation and earlier CKD detection

Status: focused, partial. Sefaxersen Phase 3 interim and original registry, new kidney-program discovery; checked announcements after prior atacicept/EASi/finerenone findings.

Gaps: Sefaxersen magnitude and safety details withheld. Full eculizumab transplant paper PMID42763038 not appraised; no outcome claim added. Early-detection and global disease-specific census incomplete.

Informal sources: National Kidney Foundation September 24 podcast show notes describe established BP/kidney testing, not new trial claims; full 45-minute audio not reviewed. https://www.kidney.org/podcasts/hot-topics-kidney-health/mended-hearts-blood-pressure-and-kidney-disease-connection . Finerenone/Vera podcasts repeat saved evidence; no new development rumor selected.

Sources checked: Source 1; Source 2; Source 3.

Bone health, joint preservation and cartilage repair

Status: focused, partial. Lorecivivint EMA/TG-C/EB613 searches, new osteoporosis trial discovery, TST002 primary abstract and comparative Phase 2 registry.

Gaps: Lorecivivint actual EMA submission still unverified; September sponsor forecast not yet elapsed. Full engineered-cell osteoporosis and TST002 papers not appraised; no causal fracture-prevention claim from headlines. Broader cartilage/function trial census incomplete.

Informal sources: Targeted Reddit osteoporosis/lorecivivint searches mainly recovered treatment anecdotes and previously reported stem-cell coverage. No distinct new trial rumor selected. Example: https://www.reddit.com/r/osteoporosis/comments/1wo5lr8/looking_for_stories_for_hope_late_30s_just_got/ . Full podcast review not performed.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6.

Non-opioid acute and chronic pain therapies

Status: focused, partial. NOHARM original trial and suzetrigine diabetic-neuropathy registry; selected September non-opioid trial/conference discovery.

Gaps: VX-993, Tonmya and full PAINWeek source packets not comprehensively refreshed. Suzetrigine DPN registry remains recruiting with estimated April 6, 2027 primary completion, not a current result.

Informal sources: Reddit Journavx/CRPS anecdotes searched; no new source-grounded development claim selected. Patient experiences were not recast as trial efficacy.

Sources checked: Source 1; Source 2.

Hearing and vision preservation/restoration

Status: focused, partial. BRUNELLO and OCU400 announcements; AC102, Rincell and paliroden registry refreshes; selected inherited/acquired hearing and retinal-program discovery.

Gaps: Complete EURETINA/Retina Society/AAO source packets, PRIMA and otarmeni label/status not refreshed. AudioCure record is still January 16; actual completion and 2027 program dates unconfirmed. Rincell remains not-yet-recruiting with estimated November start; paliroden estimated January 2027 start, not actual enrollment. SENS-601 authorization and additional September retinal-development leads not fully resolved.

Informal sources: Revisited original AC102 purported-email thread and sponsor tinnitus material; no new corroboration. Other retinal Reddit discussions largely repeated sponsor outlooks.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5.

Hair loss and hair restoration

Status: focused, partial. Searched pattern hair loss, alopecia areata and biological graying programs, including PP405, ABS-201, Veradermics, Cosmo, Kintor and new registries. Retrieved AWAKEN, HEADLINE, BioCopper and aHFS records. Bempikibart September 30 presentation remains future.

Gaps: AWAKEN still not yet recruiting in September 18 record; September start is estimated, not confirmed. Full Kintor Chinese registry/filing reconciliation, all late-stage safety tables and complete investor webcasts remain unreviewed. No new BioQ candidate-specific trial or dated BQ-002 start verified.

Informal sources: Rechecked original BQ-002 timing post and sponsor website; existing rumor unchanged. Rechecked Cosmo filing guidance; it does not verify community launch predictions. A September 25 PP405 Reddit comment says the latest email was from late August and forecast a fall start; this is secondhand email attribution without the original email and adds no confirmed recruitment. https://www.reddit.com/r/tressless/comments/1wh8oo6/pelage_pharmaceuticals_phase_3_trials_for_pp405/ . September 23 Well podcast show notes mention hair supplements, but no trial-specific statement or transcript was appraised.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7; Source 8.

Skin aging, laxity and regeneration

Status: focused, partial. Searched human skin rejuvenation, topical regimens, energy procedures and regenerative approaches. Appraised September 23 aHFS announcement and original observational protocol; linked the new gray-hair study’s secondary skin outcomes without treating them as results.

Gaps: Full aHFS conference abstract, study design and safety tables unavailable in the release. KB304 and FDA RF-microneedling safety files were not fully reappraised in this pass. September 17 serum RCT and other small cosmetic studies remain lower-priority full-text appraisal gaps; no comprehensive rare-harm review.

Informal sources: Searched podcasts and informal sources. September 17 Anna Cabeca/Mamina show description and timestamps cover established procedures, retinoids and emerging directions; no precise new in-scope trial forecast verified. September 21 Lira Clinical EXO-tech episode is a branded delivery-technology discussion, with no verified human trial result; full audio not reviewed. https://www.podparadise.com/episodes/34592498/ ; https://podfollow.com/lira-clinical-podcast-a-skindepth-convo/view

Sources checked: Source 1; Source 2; Source 3; Source 4.

Facial volume restoration and contour

Status: focused, partial. Searched new fillers, fat transfer, post-weight-loss restoration, retention and safety. Added newly registered one-year macrofat cohort; deduplicated prior KPRE/Adipeau pilot and historical filler evidence.

Gaps: Macrofat protocol has retrospective registration and unfinished scale wording; no results. September 24 Nanofat 2.0 conference abstract primarily describes processing of donor tissue; no verified comparative patient outcome was promoted. No comprehensive fresh FDA filler inventory or rare-complication review.

Informal sources: September 16 Vain-ish episode description discusses BBL complications and fat grafting but no named new facial clinical-development milestone. September 25 practitioner commentary on a celebrity’s facial fat-graft experience is anecdotal/secondhand and was not promoted to a general safety incidence or formal-program signal. Full audio not reviewed. https://podcasts.apple.com/sg/podcast/botched-surgeries-brazilian-butt-lift/id1824105551?i=1000790079738 ; https://www.mustafaaydinol.com/fat-transfer-to-face-gone-wrong/

Sources checked: Source 1; Source 2.

Scar prevention, treatment and stretch marks

Status: focused, partial. Searched new human scar, keloid and stretch-mark therapies; refreshed Geneva verteporfin, SCARFREE and SPARC/IL4-RA registries, and Syntara original news. Prior dry-needling/nanovesicle findings deduplicated.

Gaps: Geneva and SCARFREE still not yet recruiting with elapsed estimated starts; no results. SNT-9465 Q3 recruitment forecast not independently confirmed as achieved. September 8 siRNA paper remains a full-text gap; NCT06138964 still unknown/stale. Scar-laser meta-analysis located but original constituent studies not newly appraised, so no new primary efficacy event.

Informal sources: September 23 comments on an older ReverseRhinoplasty thread describe personal verteporfin/retinoic-acid procedures and claimed hair regrowth; these are self-experimentation/case anecdotes without a formal study, excluded. No new named formal-development rumor selected. https://www.reddit.com/r/ReverseRhinoplasty/comments/1uf4elm/healing_wounds_with_reduced_scarring_verteporfin/

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6.

Pigmentation and uneven skin tone

Status: focused, partial. Searched vitiligo, melasma, PIH and skin-tone therapies; newly matched original DelVito registration. Previously logged photothermal-PRP and multicomponent tomato-extract trials deduplicated. September 30 EADV remains upcoming.

Gaps: No full reappraisal of STOP-V, KT-939 or all EADV poster data; meeting has not occurred. Delayed pigmentation recurrence and long-term safety remain gaps; DelVito has no controlled efficacy results.

Informal sources: September 9 JCMS episode 106 with Kirk Barber, Vincent Richer and Allison Sutton discusses longer oral-tranexamic-acid use and thrombosis considerations; show notes do not announce a new trial or result. Full transcript/audio not appraised, so no quotation or clinical recommendation inferred. https://podcasts.apple.com/ie/podcast/episode-106-treating-melasma-for-the-long-term-the/id1398257291?i=1000788746788

Sources checked: Source 1; Source 2; Source 3.

Acne and rosacea

Status: focused, partial. Searched new acne/rosacea therapies, vaccines, devices and comparative evidence; refreshed SP0268 and redness-study registries and retrieved new-to-watch RF comparison. Noninterventional biomarker/diet association papers not treated as treatment results.

Gaps: SP0268 remains recruiting, estimated November 2028 completion, no results. Redness trial NCT07521462 unchanged. RF study has internal timing conflicts. Neurogenic-rosacea systematic review lacks accessible numerical abstract; full evidence appraisal pending. LUT014 EADV acneiform-rash lead concerns EGFR-cancer-treatment toxicity, not ordinary acne, and was not conflated with this topic.

Informal sources: September 23 Well episode with Ginni Mansberg and Cath Mahoney discusses rosacea triggers and hair supplements; accessible show notes contain no specific trial milestone. Full audio not reviewed. https://podcasts.apple.com/nl/podcast/rosacea-triggers-the-ultra-processed-brain-what-to-do/id1114694012?i=1000791343971

Sources checked: Source 1; Source 2; Source 3; Source 4.

Dental alignment, regeneration and repair

Status: focused, partial. Searched tooth regeneration, preservation/repair, aligner/braces materials, monitoring, acceleration and retention. Appraised full September 18 pulpotomy RCT and registry; refreshed direct-printed aligner record and Toregem news.

Gaps: Pulpotomy paper/registry enrollment and follow-up discrepancies unresolved. Direct-printed-aligner NCT07496892 still not yet recruiting despite September 20 estimated completion. Toregem news still ends with August events; jRCT original page did not render, Phase IIa first dosing unverified. New retention/root/gum and enamel trials not comprehensively appraised.

Informal sources: September 25–26 Reddit tooth-regrowth posts repeat TRG035 background and extrapolate to replacing implants/dentures, without new original efficacy evidence; not a new trial milestone. September 22 VERDRAHTET episode 117 describes aligner history and supervision rather than research results. https://www.reddit.com/r/MichaelLevinBiology/comments/1wpxxo0/japan_is_trialing_a_drug_that_regrows_human_teeth/ ; https://podcasts.apple.com/at/podcast/folge-117-aligner-die-wahre-geschichte/id1595615093?i=1000791048835

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5.

Allergy and airway disease

Status: focused, partial. Rademikibart asthma and VIASKIN VITESSE registry snapshots; targeted COPD readout/BLA and ERS follow-up discovery.

Gaps: Current DBV press-page access failed; no new BLA acceptance or completed filing verified. Rademikibart COPD September/Q3 readout window remains unconfirmed and has not elapsed on September 27. Full ERS abstracts, food/environmental allergy and all relevant registries not appraised. Stale VITESSE registry enrollment should not replace sponsor actual trial counts.

Informal sources: Reddit investor anticipation and a secondary DBV transcript surfaced; underlying conference recording not reviewed. Forecast repetition is not evidence of results or regulatory action.

Sources checked: Source 1; Source 2; Source 3.

Infectious-disease prevention and treatment

Status: focused, partial. SOLARIO original publication recovered; antibiotic/phage/new-class and prevention discovery; mRNA-1010 registry checked.

Gaps: SASPject PT3.9 September 17 MHRA authorization lead appeared in search indexing, but the primary news page rendered older items; not promoted as verified. BioVersys RIVTARGET/RIVCARE and alpibectir September status leads require detailed primary/registry reconciliation. ENCORE full tables, Utebzi availability/labels and antiviral/long-acting-prevention registry sweep incomplete. mRNA-1010 results-posted September 16 flag verified, but posted tables not reanalyzed; prior efficacy event retained.

Informal sources: Targeted phage/antibiotic/HSV Reddit searches were dominated by preclinical or AI-generated summaries; excluded as human-development findings. Not an exhaustive informal-source review.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6.

Genetic screening and risk prediction

Status: focused, partial. September 6–27 genetic-screening discovery: full pharmacogenomic hypertension paper, chronic-disease risk, newborn sequencing, reproductive testing and PRS discussions. Deduplicated prior PGT-A and genetic-enrichment findings.

Gaps: Full prospective utility/ancestry-calibration census incomplete; commercial embryo-score whitepaper and current professional-guidance/advertising decisions not fully appraised. No measured long-term polygenic-embryo offspring outcome verified.

Informal sources: September 23 Reddit newborn-genomics review discussion repeats prior studies; no new prospective clinical-outcome rumor verified. Commercial embryo models were not converted into offspring outcomes. https://www.reddit.com/r/heredity/comments/1wofudt/international_experiences_of_genomic_newborn/

Sources checked: Source 1; Source 2.

Informal-claim follow-up

No new rumor alert or material confirmation/retraction was established in the selected checks.

  • enobosarm_2026-09-09_cantor_phase3-direction — unconfirmed: No new confirmation of proposed Phase 3 scale/start in reviewed company sources; PLATEAU Q1 2027 interim forecast persists. Original Cantor audio remains unreviewed. Veru press releases.
  • Wegovy_2026-09-18_CHMP-MASH-outcome-unclear — unconfirmed: EMA current Wegovy overview does not resolve the September MASH procedure; absence is not evidence of rejection or delay. EMA current Wegovy EPAR.
  • ac102_reddit_email_2026_08_29_phase3_tinnitus_2027 — unconfirmed: Original purported-email claim remains unconfirmed. NCT05776459 still reflects January 16, active-not-recruiting, with estimated February 28 primary completion and July 31 study completion; neither is actual. No official confirmation of conditional 2027 phase-3/tinnitus plans found. Acute sudden hearing loss is distinct from chronic tinnitus. Original AC102 Reddit thread; ClinicalTrials.gov NCT05776459; AudioCure tinnitus research statement.
  • obicetrapib_attia_davidson_2026_09_14_alz_prevention_discussion — unconfirmed: Formal SPINOZA program existence remains independently established, but registry still says not-yet-recruiting with estimated September 2026 start. No new cognitive-prevention benefit established. Public episode material is not a fully appraised paid transcript. Michael Davidson on The Drive; ClinicalTrials.gov NCT07794670.
  • mount_sinai_2026-09-22_ibd_cart_planning — unconfirmed: Saurabh Mehandru’s attributed planning statement remains a planning signal, without verified new trial initiation. The separate September 23 BCMA CAR-T enterocolitis study neither confirms this proposed IBD trial nor establishes IBD treatment efficacy. OncLive CAR-T discussion.
  • clascoterone_2026-07-26_reddit_us-launch-inference — unconfirmed: Rechecked Cosmo July 23 primary guidance: Q1 2027 U.S. filing and Q2 2027 Europe filing remain forecasts. No verified approval/launch date; community late-2027/2028 inference stays unconfirmed. Cosmo filing guidance.
  • bq002_2026-05-01_reddit_phase1-2027 — unconfirmed: Rechecked original post and BioQ website. Candidate existence remains corroborated, but candidate-specific human registration, trial start and 2027 date remain unverified. Company-level clinical-stage language and marketing claims are not trial outcomes. Original community claim; Sponsor pipeline.

Interpretation and publication

Galleri votes are nonbinding and do not establish approval or mortality benefit. CT-388 has an unresolved week-36 registry versus week-48 release discrepancy; no new plot values were inserted. BELIEVE abstract availability precedes its scheduled September 30 presentation; original posting date is unknown. Small null trials do not establish equivalence. Individual tumor response and PFS results do not imply overall-survival benefit.

The notebook was verified before public export. Publication is tracked separately from research verification; the public research edition excludes personal notes and identifying context.